Can Tadalafil Cause Subconjunctival Hemorrhage?
Tadalafil is not directly listed as a cause of subconjunctival hemorrhage in the FDA drug label, but conjunctival hyperemia (conjunctivitis) is a recognized adverse effect, and there is case report evidence suggesting tadalafil may contribute to ocular hemorrhagic events in patients with underlying vascular abnormalities.
Evidence from FDA Drug Label
The official FDA labeling for tadalafil lists conjunctivitis (including conjunctival hyperemia) as an ophthalmologic adverse reaction 1. However, subconjunctival hemorrhage specifically is not mentioned in the adverse events profile. The drug label does note various vascular effects including:
- Conjunctivitis with conjunctival hyperemia
- Changes in color vision (rare, <0.1%)
- Blurred vision
- Eye pain and swelling of eyelids
Clinical Evidence of Hemorrhagic Complications
While subconjunctival hemorrhage per se is not in the FDA label, there is documented evidence of more serious hemorrhagic ocular complications:
A case report describes subfoveal (retinal) hemorrhage occurring 1 hour after tadalafil use in a patient with previously undiagnosed retinal angiomatous proliferation 2. Though this involved deeper retinal structures rather than subconjunctival space, it raises concern about tadalafil's potential to contribute to ocular bleeding, particularly in patients with pre-existing vascular abnormalities.
The authors of this case specifically recommend caution in prescribing phosphodiesterase type 5 inhibitors to patients with known vascular abnormalities including retinal and choroidal abnormalities 2.
Mechanism and Plausibility
Tadalafil works by inhibiting phosphodiesterase type 5, causing vasodilation through increased cyclic GMP. This mechanism could theoretically:
- Increase conjunctival blood flow
- Cause conjunctival vessel engorgement (documented as conjunctival hyperemia)
- Potentially contribute to vessel rupture in susceptible individuals
A comprehensive review of PDE5 inhibitor visual side effects notes multiple ocular vascular complications including chorioretinopathy and retinal occlusion, though subconjunctival hemorrhage is not specifically highlighted 3.
Clinical Recommendation
While subconjunctival hemorrhage is not an established adverse effect of tadalafil, the drug's vasodilatory properties and documented conjunctival hyperemia suggest it could be a contributing factor, especially in patients with:
- Pre-existing conjunctival vascular fragility
- Concurrent anticoagulation or antiplatelet therapy (notably, tadalafil did not potentiate aspirin-induced bleeding in studies 1)
- Underlying retinal or choroidal vascular abnormalities
- Activities involving Valsalva maneuver (which independently causes subconjunctival hemorrhage)
If a patient on tadalafil presents with subconjunctival hemorrhage:
- Document timing relative to drug use
- Assess for other contributing factors (trauma, Valsalva, anticoagulation, hypertension)
- Perform dilated fundus examination to rule out deeper retinal hemorrhage, particularly if there are visual symptoms
- Consider discontinuation if recurrent hemorrhages occur
- Exercise particular caution in patients with known retinal vascular disease
The hemorrhage itself is typically benign and self-limited, but the association warrants documentation and consideration of alternative therapy if recurrent.